Clarification of NICE guidance on prostate cancer
Following detailed discussion with BAUS, the National Institute for Health and Clinical Excellence (NICE) published clarification on its clinical guideline on ''Prostate Cancer: diagnosis and treatment'' in June 2009 [1] . This clarification will be welcome to men with prostate cancer, urologists and oncologists alike.
Research into prostate cancer is continuing to improve. We now know that men with prostate cancer treated surgically have better survival than those treated by watchful waiting [2] . We know that PSA screening for prostate cancer reduces death from prostate cancer, albeit at a considerable price of over-diagnosis and over-treatment [3, 4] . The genetics of the disease is becoming clearer [5] and the molecular biology of the disease is gradually being uncovered [6, 7] . Better understanding of how androgen resistant prostate cancer develops [8, 9] is leading to novel drugs [10, 11] . Other high quality randomised trials such as the Pro-tecT study [12] and RADICALS will inform us in the future as to the effectiveness of surgery, radiotherapy and active monitoring for screen detected prostate cancer, and of the role of radiotherapy in men with high risk disease at radical prostatectomy [13] .
The utility of guidelines is critically dependent on the robustness of the evidence underpinning them; evidence that is only produced by high quality research. As noted by Archie Cochrane in his 1972 Rock Carling Lecture ''health services should be evaluated on the basis of scientific evidence rather than on clinical impression, anecdotal experience, 'expert' opinion or tradition'' [14] . The British Association of Urological Surgeons (BAUS) is strongly supportive of NICE and its work and agrees with most of the recommendations in the Guideline. However some of the most prescriptive recommendations were not underpinned by good evidence.
Well before the publication of the NICE Guideline in February 2008 [15] , vigorous efforts had been made by BAUS, Cancer Research UK (CR UK) and others to try to ensure that the recommendations better reflected the quality of the evidence. Regrettably few changes were made. Many of our reservations were shared by international commentators including Wilt, who noted [16] :
''The paucity of randomised trials limits the quality of data used for informed decision making, particularly regarding detection and treatment of localised disease. . .. Thus, it is difficult to mandate rigid adherence to these recommendations or to create national practice standards.''. . . ''Some detection, treatment, and monitoring recommendations are very prescriptive despite lack of evidence supporting this level of detail.''
Following the BAUS annual meeting in 2008, a series of meetings were set up between BAUS and NICE to try to reach agreement and to ensure that BAUS could strongly support the implementation of this Guideline. It is fair to say that it took some time for both groups to agree a constructive way forward. 
Low risk prostate cancer
We are very clear that men should be offered neutral advice about the management of prostate cancer. Many men with low risk prostate cancer do not require radical treatment and the evidence from the ProtecT trial is that when neutral counselling takes place, men and their relatives appreciate this and make an informed choice [12] . Indeed BAUS has strongly supported the development of an informed decision making project in this area [17] . The D'Amico risk classification criteria proposed in the NICE guidelines is related to biochemical recurrence after radical prostatectomy or exter-nal beam radiotherapy [18] , although they have the advantage of being easily utilised.
It would be a good idea if men with low risk prostate cancer were offered protocols so that only those at risk of progression were offered radical treatment. Unfortunately these have not yet been defined, tested formally through randomised trials, further refined, and published [16, 19] . It should be remembered that repeated prostate biopsies carry significant risks of infection and bleeding, and may have as yet undefined biological effects on tumour behaviour. It was therefore a real concern to BAUS that NICE was offering a very prescriptive approach to the use of Active Surveillance which was mandated in the guidance to include repeated biopsies.
Also, the wording of the guidance for men with low risk prostate cancer gave the impression to most readers that all men with low risk prostate cancer were to be offered only Active Surveillance. This is clearly not appropriate for all men.
BAUS wanted to see both these aspects clarified so that urologists and oncologists were able to offer a range of appropriate treatments, albeit with an emphasis on a conservative approach, and also wanted to see urologists being able to offer both Active Surveillance with a biopsy and active monitoring without a biopsy.
Hormonal treatment
We completely agree that there are significant deleterious effects of long term androgen suppression [20] , but felt that a 3-month doubling time as an indication for hormonal ablation was far too restrictive [21] [22] [23] [24] . The other problem is that measuring doubling time accurately in the clinic is quite difficult and there is continued debate over whether such measurements represent any improvement over simple measurement of PSA alone [25] [26] [27] [28] . We wanted to see this recognised.
HIFU and cryotherapy
BAUS is including cryotherapy in its set of complex procedures for a national audit and NICE has agreed that this represents its use in a controlled trial situation. However we are strongly of the view that new technology requires careful assessment in proper clinical trials with clinically appropriate endpoints. We remain concerned about industry-led introduction of new technology in early prostate cancer and we agree with this recommendation from NICE and hope to see NIHR sponsored clinical trials of cryotherapy in the near future.
Bisphosphonate use
Our view is that bisphosphonates have been overpromoted as drugs to treat cancer, but that there is good evidence that they can reduce androgen deprivation induced bone loss and the subsequent skeletal events and pain. A Cochrane review in 2006 [29] also demonstrated benefit in these areas and the recommendation from NICE was a little surprising. A recent report on an MRC study on one of the early bisphosphonates showed survival benefit. We wanted also to be sure that men on androgen deprivation therapy were tested to determine if they were at risk of osteoporosis because the recent NICE guidance on osteoporosis is currently suspended [30] .
Follow-up
There is marked variability in the success and rigour of primary care led prostate cancer follow-up. There is no doubt that this can work well, provided systems and protocols are set up which will trigger appropriate re-assessment. In particular as new research-based information comes through to routine clinical practice, treatment protocols and triggers for reassessment will change. It is also critical for high quality clinical research that outcomes of treatment are fed back to the urological and oncology departments. BAUS did not believe that these lines of communication were ideal in many parts of the country.
Outcome of consultation with NICE and clarification statement
The outcomes are summarised in Fig. 1 . NICE has published this clarification and altered its implementation guidelines and slide pack. This clarification re-introduces flexibility which reflects real-life clinical practice. Men with low risk prostate cancer suitable for radical treatment will be told about a range of treatment options including Active Surveillance, radiotherapy and surgery. The decision about when and whether to carry out a re-biopsy should be made in consultation with the local multi-disciplinary team. The actual level of PSA and some flexibility around the definition of doubling times have been introduced.
Because long term androgen deprivation is associated with osteoporosis, before men start androgen deprivation therapy assessment should normally be made of their individual risk. Local protocols should be developed which prior to androgen deprivation would include measurement of bone density, and assessment of risk based on site of metastases and which would include triggers for starting chemo-preventative treatment to reduce risk of future bone complications.
So far as follow-up is concerned, it is now expected that primary care led follow-up will happen only if agreed between doctor, patient and GP in accordance with protocols agreed by the local urological cancer MDT and the relevant primary care organisation(s).
We hope these changes will be welcomed by the urological and oncological community, and we think that they will benefit patients.
Joint Implementation Statement
The British Association of Urological Surgeons (BAUS) welcomes the National Institute for Clinical Excellence (NICE) prostate cancer guideline and are keen to work with NICE in supporting its implementation. Since its publication BAUS and NICE have had discussions to ensure that there is clarity over some of the recommendations in order to support the implementation of the guideline. It has been decided that a joint statement should be added to the implementation support documents. The statement applies to: The management of patients with low risk prostate cancer It is expected that men with low risk prostate cancer suitable for radical treatment will be told about a range of treatment options including Active Surveillance, radiotherapy and surgery. This is to ensure that a fully informed joint decision on future care is made by the patient and his doctor. For patients choosing Active Surveillance, the decision about when and whether to carry out a re-biopsy should be made in consultation with the multi-disciplinary team. Hormonal therapy for biochemical relapse after primary treatment In asymptomatic men with biochemical progression after radical treatment, because of long lead times and difficulty in accurately measuring PSA doubling times, hormonal treatment should normally be deferred until PSA doubling times are around 3 months and account should be taken of the actual level of PSA. In men with symptomatic recurrence or with bone metastases, hormone therapy should normally be started at the time these problems are detected.
Bisphosphonates and osteoporosis
The use of bisphosphonates to prevent or reduce the complications of bone metastases in men with hormone-refractory prostate cancer is not recommended. Bisphosphonates for pain relief may be considered for men with hormone-refractory prostate cancer when other treatments (including analgesics and palliative radiotherapy) have failed. The oral or intravenous route of administration should be chosen according to convenience, tolerability and cost. Strontium-89 should be considered for men with hormone-refractory prostate cancer and painful bone metastases, especially those men who are unlikely to receive myelosuppressive chemotherapy. Bisphosphonates should not be used routinely to prevent osteoporosis in men with prostate cancer receiving androgen withdrawal therapy. However because long term androgen deprivation is associated with osteoporosis, before men start androgen deprivation therapy assessment should normally be made of their individual risk. Local protocols should be developed which prior to androgen deprivation would include measurement of bone density, and assessment of risk based on site of metastases and which would include triggers for starting chemo-preventative treatment to reduce risk of future bone complications. Follow-up of men with localised prostate cancer Healthcare professionals should discuss the purpose, duration, frequency and location of follow-up with each man with localised prostate cancer, and if he wishes, his partner or carers. Men with prostate cancer should be clearly advised about potential longer term adverse effects of treatment and when and how to report them. If agreed between doctor, patient and GP, then men with prostate cancer who have chosen a watchful waiting regimen with no curative intent should normally be followed up in primary care in accordance with protocols agreed by the local urological cancer MDT and the relevant primary care organisation(s). Their PSA should be measured at least once a year.
